-
Kuros Biosciences Reports Results for First Half 2020
CHF 16.0 million cash & cash equivalents, trade and other receivables as at June 30, 2020 Revenues increased to CHF 1.3 million driven by strong MagnetOs sales, up 42% versus H1 2019 Net operating costs of CHF 7.5 million led by higher marketing expenses Several trial sites activated for the Fibrin-PTH phase II clinical study, ready to enroll patients Strengthened Fibrin-PTH IP estate with U.S. patent covering PTH containing matrices for spinal fusion MagnetOs preclinical data demonstrate superiority to market-leading synthetic bone grafts in spinal fusion Positive clinical outcomes from investigator-led clinical study of MagnetOs Kuros Biosciences, a leader in next generation bone graft technologies, today reported its results for…
-
Kuros Biosciences further strengthens orthobiologics patent portfolio
. Grant of European patent entitled ‘Osteoinductive composites’ Notice of allowance of Japanese patent from the same patent family Further strengthens Kuros’s position as a leader in the field of orthobiologics Kuros Biosciences (SIX: KURN) today announced that its Dutch subsidiary, Kuros Biosciences BV, has been granted the European patent, EP 3268058, entitled ‘Osteoinductive composites’. This patent covers certain combinations of polymers and granular materials and further expands Kuros’s patent portfolio relating to its MagnetOs product line. Kuros has also received notice of allowance of a patent application from the same patent family in Japan. Kuros has over 20 granted patents and more than 10 patents pending, specifically in the…
